Compare AVAV & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVAV | GH |
|---|---|---|
| Founded | 1971 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 13.3B |
| IPO Year | 2006 | 2018 |
| Metric | AVAV | GH |
|---|---|---|
| Price | $213.79 | $84.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 20 |
| Target Price | ★ $329.38 | $117.80 |
| AVG Volume (30 Days) | ★ 1.9M | 1.6M |
| Earning Date | 06-09-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | $147.25 | $33.40 |
| Revenue Next Year | $17.15 | $28.55 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $102.25 | $36.36 |
| 52 Week High | $417.86 | $120.74 |
| Indicator | AVAV | GH |
|---|---|---|
| Relative Strength Index (RSI) | 38.57 | 27.01 |
| Support Level | $196.22 | $54.39 |
| Resistance Level | $279.29 | $114.53 |
| Average True Range (ATR) | 20.90 | 4.54 |
| MACD | -1.73 | -0.84 |
| Stochastic Oscillator | 15.78 | 9.43 |
AeroVironment Inc supplies unmanned aircraft systems, tactical missile systems, high-altitude pseudo-satellites, and other related services to government agencies within the United States Department of Defense as well as the United States allied international governments. The systems can help with security, surveillance, or sensing, and provide eyes in the sky without needing an actual person, or driver in the sky. The company is a defense technology provider delivering integrated capabilities across air, land, sea, space, and cyber. It develops and deploy autonomous systems, precision strike systems, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities. Company operates in three segments: UxS, LMS, MW.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.